Ironwood Pharmaceuticals | IRWD - Cost Of Sales


Ironwood Pharmaceuticals reported $29.83M in Cost of Sales for its fiscal quarter ending in September of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Akebia Therapeutics USD 10.34M 441K Dec/2025
Almirall EUR 199.26M 7.76M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amarin USD 26.05M 1.41M Dec/2025
Ardelyx USD 4.81M 6.04M Mar/2026
Astellas Pharma JPY 158.38B 28.94B Jun/2026
AstraZeneca USD 2.52B 2.73B Jun/2026
Charles River Laboratories USD 655.29M 61.22M Jun/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Halozyme Therapeutics USD 108.68M 67K Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Lexicon Pharmaceuticals USD 201K 191K Dec/2025
MacroGenics USD 9.53M 585K Mar/2026
Moderna USD 93M 862M Jun/2026
Myriad Genetics USD 63M 1.1M Dec/2025
Pacira USD 58.49M 7.75M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Takeda JPY 517.6B 42.94B Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024